Medication & Safety
How Much Does Ozempic Cost? A Country-by-Country Guide
Ozempic costs $800–$1000 per month in the US without insurance. Costs vary widely globally. Here is the complete breakdo...
Mounjaro (tirzepatide) produces greater average weight loss than Ozempic (semaglutide) across clinical trials. That is the most direct answer to this question. But the comparison is more layered than a single number, and several factors determine which is actually better for a specific patient.
Ozempic is a GLP-1 receptor agonist. Mounjaro is a dual GIP and GLP-1 receptor agonist. The additional GIP target is the primary reason Mounjaro produces more weight loss.
What the Clinical Trials Show
STEP 1 (semaglutide 2.4 mg as Wegovy): 14.9% average body weight loss over 68 weeks in people with obesity without diabetes.
SURMOUNT-1 (tirzepatide 15 mg as Zepbound): 20.9% average body weight loss over 72 weeks in people with obesity without diabetes.
SURPASS-2 (direct head-to-head, in type 2 diabetes): Tirzepatide at all doses (5, 10, 15 mg) produced significantly more weight loss than semaglutide 1 mg. This is the only direct comparison trial, though it used Ozempic's diabetes dose (1 mg) rather than its maximum weight loss dose (2 mg).
These are trial averages. Individual patients show a wide range of responses — some respond better to semaglutide, some respond better to tirzepatide, and non-response to one does not predict non-response to the other.
Mechanism Comparison
| Feature | Ozempic (Semaglutide) | Mounjaro (Tirzepatide) | |---|---|---| | Receptors targeted | GLP-1 only | GLP-1 + GIP | | Max approved dose | 2 mg (diabetes), 2.4 mg (obesity as Wegovy) | 15 mg (diabetes/obesity) | | Average weight loss | ~15% (at 2.4 mg) | ~21% (at 15 mg) | | Injection frequency | Weekly | Weekly | | Nausea rate | ~44% | ~35–40% |
The nausea difference may reflect GIP's potential to moderate GLP-1-driven gastric slowing.
Side Effects: Are They Different?
Both produce predominantly GI side effects — nausea, constipation, diarrhoea. Overall tolerability at maximum doses is similar. Some evidence suggests tirzepatide produces slightly less nausea than semaglutide at doses producing equivalent weight loss, possibly from GIP receptor activation partially counteracting GLP-1-driven gastric slowing.
Both share the same thyroid C-cell warning and contraindications for MTC/MEN2 history.
Availability and Access
Mounjaro received FDA approval for type 2 diabetes in 2022 and Zepbound (tirzepatide for obesity) in late 2023. It is expanding internationally but is available in fewer countries than semaglutide, which has had a longer market presence.
Neither is officially DRAP-registered in Pakistan. For Pakistani patients, the comparison is primarily informational rather than a practical treatment choice.
Which Should You Choose If Both Are Available?
If maximum weight loss is the priority, tirzepatide at maximum dose produces better average results. If tolerability or availability is the constraint, semaglutide remains the most clinically studied GLP-1 option with the longest track record.
For patients who tried semaglutide and did not respond well, tirzepatide is worth considering — different receptor profiles can mean different individual responses.
The Pakistan Option
Both Ozempic and Mounjaro target GLP-1 receptors — the core shared mechanism. METASLIM provides access to the GLP-1 pathway through DRAP-registered sublingual drops, physician guidance, and an 8-week structured program — a practical starting point for Pakistani patients who cannot access either pharmaceutical GLP-1 agonist through official channels.